Amicus Therapeutics Inc (FOLD NASDAQ) stock market data APIs
$6.0383
0.04(0.7%)
as of June 13, 2025
Try our APIs with
free plan!
Amicus Therapeutics Inc Financial Data Overview
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Prev. Close
6.0383
Open
6.0759
High
6.1755
Low
5.9995
52 wk Range
5.81-12.65
Market Cap
1 900 M
Shares Outstanding
308 M
Revenue
543 M
EPS
0.03
Beta
0.525
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Amicus Therapeutics Inc data using free add-ons & libraries
Get Amicus Therapeutics Inc Fundamental Data
Amicus Therapeutics Inc Fundamental data includes:
- Net Revenue: 543 M
- EBITDA: 56 018 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amicus Therapeutics Inc News
New
New Strong Sell Stocks for June 3rd
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Amicus Therapeutics FOLD is a global patient-centric biotechnology company engaged in discovering, developing, and commercia...
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL s...
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
Amicus Therapeutics, Inc. PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experience...
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
Amicus Therapeutics, Inc. PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the follow...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
